• Hoth Therapeutics Inc (NASDAQ: HOTH) has announced that its HT-003 group of assets has yielded positive results in an in vivo acne therapeutic model.

• The model showed that HT-003 reduces toll-like receptor 2 (TLR2) expression, one of the most critical pathways for acne pathophysiology.

• The study also showed that HT-003 reduces the expression of numerous cytokines critical for acne pathophysiology that are also relevant therapeutic markers for other inflammatory-driven skin diseases.

• HT-003 is a group of retinoic acid metabolism blocking agents, novel agents that prevent the breakdown of retinoic acid. Retinoic acid acts as an anti-inflammatory agent in the body.

• In addition to the dermatologic application, Hoth Therapeutics is exploring the potential application of HT-003 assets in inflammatory bowel disorders.

• Price Action: HOTH shares are down 2.01% at $1.46 during the market session on the last check Tuesday.

See more from Benzinga

• Click here for options trades from Benzinga

• Genocea Biosciences Starts Dosing In Mid-Stage GEN-011 Study In Solid Tumors

• InVivo Therapeutics Stock Moves Higher On FDA Acceptance Of Preclinical Module For Neuro-Spinal Implant

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.